Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
艾希林股票下跌，因爲該公司宣佈其Izokibep的2b/3期研究未能達到主要終點，且次要終點也未能達到統計學意義。
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
Acelyrin宣佈其Izokibep的2b/3階段研究未達到其主要終點，次要終點也未能達到統計學意義，此後，Acelyrin股價走低。
熱門討論
特朗普2.0時代倒計時！全球股市的下一個風口？
🎙️️討論： 1. 加密貨幣政策能否利好crypto? 2. 關稅政策能否利好中概等海外資產？
Popular on moomoo
01/13 17:43
特朗普2.0機會預告：在總統上任之前猜測市場贏家！